
Sign up to save your podcasts
Or


The advent of targeted therapies has contributed to notable progress in the fight against cancer, but the ability of cancers to develop resistance to these precision medicines continues to leave patients in need of new approaches. Concarlo Therapeutics is developing therapies that target a critical driver of cell proliferation that is reactivated once a cancer grows resistant to certain targeted therapies. We spoke to Stacy Blain, co-founder and chief scientific officer of Concarlo, about the development of drug resistance in cancer, the company’s initial focus on breast cancer, and her own journey from academia to biopharma.
By Levine Media Group3.7
3939 ratings
The advent of targeted therapies has contributed to notable progress in the fight against cancer, but the ability of cancers to develop resistance to these precision medicines continues to leave patients in need of new approaches. Concarlo Therapeutics is developing therapies that target a critical driver of cell proliferation that is reactivated once a cancer grows resistant to certain targeted therapies. We spoke to Stacy Blain, co-founder and chief scientific officer of Concarlo, about the development of drug resistance in cancer, the company’s initial focus on breast cancer, and her own journey from academia to biopharma.

4,162 Listeners

1,705 Listeners

3,372 Listeners

2,176 Listeners

1,447 Listeners

9,519 Listeners

322 Listeners

7,237 Listeners

6,092 Listeners

34 Listeners

517 Listeners

5,511 Listeners

18 Listeners

51 Listeners

394 Listeners